Brain tumor gene mapping project launches in Seattle

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 12
Volume 18
Issue 12

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

Research on the Glioblastoma Atlas Project (GAP) is slated for completion in 2013. The resulting atlas information will then be made available online for free use by the global medical and scientific communities.

GAP will target 1,000 genes, which were selected for study by a panel of physician scientists and medical professionals led by Greg Foltz, MD, co-director of the Ivy Center for Advanced Brain Tumor Treatment. Dr. Foltz will serve as the lead investigator on the atlas.

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.